Endovia Health Sciences, Inc. (NYSE American: EDVA) announced on October 5, 2026, that the U.S. Food and Drug Administration (FDA) has determined that CannEpil® qualifies as a minor use for the control of pain associated with bone cancer in dogs. This determination establishes the product's eligibility to pursue a conditional approval pathway under the Minor Use and Minor Species (MUMS) program.
The FDA determination, issued by the Center for Veterinary Medicine, confirms that CannEpil®—an investigational oral solution containing cannabidiol (CBD) and tetrahydrocannabinol (THC)—meets the criteria for the MUMS framework. This regulatory pathway is designed to facilitate earlier availability of therapies for uncommon diseases and conditions in animals. Under conditional approval, a sponsor may legally market the drug while continuing to collect the additional effectiveness data necessary to support full FDA approval.
Endovia, in association with Lupvindol BioSciences, is scheduled to meet formally with the FDA on November 19, 2026, for a Pre-Submission Conference. The meeting will focus on aligning with the agency on the proposed development program, including required studies, manufacturing requirements, and regulatory submissions.
In parallel with the regulatory program, the companies are actively sourcing and finalizing U.S.-based manufacturing capabilities. The goal is to establish a scalable, FDA-compliant domestic supply chain capable of supporting the clinical program and, subject to regulatory approval, a potential commercial launch for veterinary use in 2027.
CannEpil® remains an investigational new animal drug and has not been approved or conditionally approved by the FDA. The anticipated development timelines, including the potential 2027 commercial launch, are subject to FDA review, successful completion of regulatory requirements, manufacturing readiness, and other factors.
